Gapping up
In reaction to earnings/guidance:
- NPTN +4.8%, AOSL +4.1% (Q1 guidance), FTV +2.7%
M&A news:
- EIDX +69.3% (BridgeBio Pharma to acquire all of the outstanding common stock of Eidos (EIDX) it does not already own)
- MYOK +58.5% (to be acquired by Bristol Myers Squibb (BMY) for $225.00/share in cash)
Select financial related names showing weakness:
- IWM +1%, SPY +0.7%, QQQ +0.7%, DIA +0.7%
Other news:
- CRVS +40.5% (announced updated data from its ongoing Phase 1 study investigating the potential for CPI-006 to provide a novel immunotherapy approach for patients with COVID-19)
- IMGN +18.1% (announces FDA breakthrough therapy designation for IMGN632 in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm)
- MGTX +9.6% (reports nine-month data from Phase 1/2 trial of AAV-RPGR demonstrating significant and sustained vision improvement)
- CYTK +9.4% (presented data at the Heart Failure Society of America Virtual Annual Scientific Meeting 2020)
- XPEV +8% (reports Q3 deliveries increased 266% to 8,578 vehicles)
- AVRO +5.6% (AVROBIO announced an exclusive, worldwide license agreement and a collaborative research funding agreement with The University of Manchester for an investigational lentiviral gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome)
- REGN +5.3% (President Trump treated with a dose of Regeneron's polyclonal antibody cocktail)
- SMMT +4.9% (announces agreement for fundraising of ~$50 million; believes that the net proceeds of the Fundraising will extend its cash runway to the third quarter of 2021)
- TRGP +4.8% (announces $500 million common share repurchase program and provides updated 2020 outlook)
- QDEL +4.5% (receives EUA for ABC Test - a combination diagnostic assay for Influenza A+B and COVID-19)
- GILT +3.8% (Gilat Satellite and Comtech Telecommunications (CMTL) terminate merger agreement)
- GILD +3.3% (President Trump is taking GILD's remdesivir for his coronavirus treatment)
- TEX +3.3% (positive Barrons article)
- TRIL +2.9% (received Notices of Allowance from the United States Patent and Trademark Office for two patent applications covering the use of SIRPaFc for the treatment of cancer)
- SRNE +2.5% (will host a R&D Day conference call and simultaneous webcast on October 13th, 2020 focusing on its comprehensive multi-modal approach to COVID-19)
- PTEN +2.3% (had an average of 60 drilling rigs operating in September and average of 60 drilling rigs operating in Q3)
- VALE +1.9% (Reuters report that co is in talks with Tesla and others about securing nickel)
- ARGX +1.6% (reports Phase 3 ADAPT data consistent with positive topline results)
Analyst comments:
- JELD +6.7% (upgraded to Overweight from Equal Weight at Wells Fargo)
- ATUS +4.2% (upgraded to Outperform from Mkt Perform at Bernstein)
- ST +3.4% (upgraded to Outperform from Market Perform at Cowen)
- INTU +3.1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- DOCU +2.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- LBRT +2.5% (upgraded to Overweight from Equal Weight at Barclays)
- OKE +2.5% (upgraded to Overweight from Equal Weight at Wells Fargo)
- HP +2.3% (upgraded to Equal Weight from Underweight at Barclays)
- PII +2.2% (upgraded to Outperform from Neutral at Robert W. Baird)
- CRWD +2.2% (resumed with a Buy at Goldman)
- CCOI +1.5% (upgraded to Mkt Perform from Underperform at Raymond James)